<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

FaDu

Description

FaDu (Hypopharyngeal Cancer CDX Model) 

The FaDu hypopharyngeal carcinoma line was derived from a squamous cell carcinoma of the pharynx. It is classified within head and neck squamous cell carcinoma (HNSCC). FaDu is widely used in studies of drug response in upper aerodigestive tract cancers. Its reproducibility makes it a cornerstone model for HNSCC research. 

Key Features: 

  • Derived from hypopharyngeal squamous carcinoma. 
  • Epithelial morphology consistent with HNSCC. 
  • Tumorigenic in xenograft systems. 
  • Models upper aerodigestive cancers. 

Applications: 
FaDu is applied in studies of HNSCC drug response, including chemotherapies and targeted agents. It supports biomarker identification for head and neck cancer treatment. Researchers often use FaDu in radiotherapy sensitivity studies. Its consistency makes it valuable for translational oncology pipelines.

Details
Tumor Type
Head and Neck
Tumor Subtype
Squamous Cell Carcinoma
Organism
Human
Mouse Sex
Female
Mouse Strain
NOG
Mutated Genes
TP53
Mutation: p.R248L
Effect: Missense Variant
Impact: Likely Pathogenic & Pathogenic
Effect: Splice Acceptor Variant
Impact: Pathogenic
VHL
Mutation: p.M1?
Effect: Start-Loss
Impact: Uncertain Significance & Conflicting Interpretations Of Pathogenicity
Lumin Data
Proteomics RNASeq WES
Expression Data
Growth Curve
View on Lumin